Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Jong-Mu Sun

11PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

Sort by Publication Date:
|Feb 06, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Eun Ji Lee, Ji Ae Ko, Min-Je Kim

|Oct 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.

Yeong Hak Bang, Geun-Ho Park, Jin Woo Oh

|Oct 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

Isamu Okamoto, Shoichi Kuyama, Nicolas Girard

|Jun 24, 2024
Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma.

Tae Hee Hong, Tae Ho Kim, Genehee Lee

|Jan 02, 2024
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.

Joohyun Hong, Jiyun Lee, Sehhoon Park

|Jul 15, 2022
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.

Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi

Pageof 2

Frequent Collaborators

3 joint publications

Myung-Ju Ahn

2 joint publications

Han Gyul Yoon

2 joint publications

Dongryul Oh

2 joint publications

Jae Myoung Noh

2 joint publications

Hong Kwan Kim

2 joint publications

Jae Ill Zo

2 joint publications

Young Mog Shim

2 joint publications

Ji-Youn Han

1 joint publications

Sun Min Lim

1 joint publications

Kyunga Kim

Frequent Collaborators

3 joint publications

Myung-Ju Ahn

2 joint publications

Han Gyul Yoon

2 joint publications

Dongryul Oh

2 joint publications

Jae Myoung Noh

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.2K
See more related videos

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.2K
See more related videos